What are the Payers Views on Long Acting Injectables?

What are the prospects of value creation through novel LAIs, the challenges associated with evidence generation, and the potential to translate value and evidence into favourable coverage decisions and pricing? Payers from different countries give their opinions in the exclusive study by GroupH and MedinCell summarized below.

Presentation mode: https://magic.piktochart.com/output/3699693-payers-views-on-lais

Share this on